Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement.
The purpose of this study was to evaluate the clinical safety of pamidronate when administered at a mean dosage of 1.0 mg/kg IV q28d in 33 tumor-bearing dogs. Biochemical tests of renal function were evaluated before each successive pamidronate treatment. Of 33 dogs treated with pamidronate, 1 dog had clinically relevant increases in serum creatinine and blood urea nitrogen concentrations. The biologic activity of IV pamidronate was assessed prospectively in 10 dogs with appendicular osteosarcoma and was assessed on reductions in urine N-telopeptide excretion (P = .042) and enhanced bone mineral density of the primary tumor measured with dual-energy x-ray absorptiometry (P = .024). Additionally, in these 10 dogs, pamidronate's therapeutic activity was supported by subjective improvement in pain control in 4 of the 10 dogs treated. IV pamidronate appears clinically safe in tumor-bearing dogs and may possess modest biologic activity for managing neoplastic complications associated with pathologic bone resorption.
Fan
Timothy M
TM
Department of Veterinary Clinical Medicine, Veterinary Teaching Hospital, University of Illinois, Urbana, IL 61802-4714, USA. t-fan@uiuc.edu
de Lorimier
Louis-Philippe
LP
Charney
Sarah C
SC
Hintermeister
John G
JG
D015502:Absorptiometry, Photon / Q000662:veterinary; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D015519:Bone Density / Q000187:drug effects; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D001862:Bone Resorption / Q000188:drug therapy / Q000662:veterinary; D003094:Collagen / Q000652:urine; D024042:Collagen Type I; D004164:Diphosphonates / Q000008:administration & dosage*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D005260:Female; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D007677:Kidney Function Tests / Q000662:veterinary; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy / Q000556:secondary / Q000662:veterinary*; D000077268:Pamidronate; D010455:Peptides / Q000652:urine
D000970:Antineoplastic Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D003094:Collagen; D000077268:Pamidronate